EPZM - Epizyme A Buy For Tazverik And Epigenetic Platform
Epizyme (EPZM) advanced from a clinical-stage company to a commercial stage company in January 2020 when Tazverik (tazemetostat) was approved by the FDA for advanced epithelioid sarcoma. Revenue from the sale of the drug was minimal in Q1 2020 but should ramp significantly over the next few years. More importantly for long-term investors, Tazverik is proof that its novel epigenetic therapies can work. I believe Epizyme could become a major pharmaceutical company over the coming decade as its platform generates more potential therapies and they progress through its pipeline. This article will review